CAJ | 학술논문

目的：：制备负载布洛芬( IPF)的新型温敏凝胶IPF/PECT,并探讨其在牙周局部缓释用药的可行性。方法：采用纳米沉淀技术制备IPF/PECT 纳米粒(IPF/PECT NPs),将其冻干并用双蒸水溶解成凝胶制剂后,分别用TEM观察其纳米粒形貌；MTT法检测其生物相容性；ELISA法测定其体外细胞抗炎效果；于37℃下观察其液-胶转变情况及药物缓释特性。结果：IPF/PECT纳米粒径均匀,无明显聚合现象；用含不同浓度(0、200、400、800、1200、1600、2000μg/mL)IPF/PECT的培养基培养牙龈成纤维细胞(HGFs)48 h后,各组间平均OD值两两相比差异均无统计学意义(P﹥0.05)；在0.1μg/mL LPS刺激下同时加入60μg/mL的IPF或IPF/PECT,并与HGFs共同培养10、24、48、72 h后,各时间点的前列腺素E2( PGE2)浓度均为IPF/PECT组明显低于IPF组(P<0.05)；IPF/PECT体外释放IPF可持续32 d以上,药物累积释放量达85%。结论：本实验所制备的新型双亲性载药温敏凝胶IPF/PECT具有良好的生物安全性和缓慢释药功能,其抗炎效果明显优于IPF水溶液。
목적：：제비부재포락분( IPF)적신형온민응효IPF/PECT,병탐토기재아주국부완석용약적가행성。방법：채용납미침정기술제비IPF/PECT 납미립(IPF/PECT NPs),장기동간병용쌍증수용해성응효제제후,분별용TEM관찰기납미립형모；MTT법검측기생물상용성；ELISA법측정기체외세포항염효과；우37℃하관찰기액-효전변정황급약물완석특성。결과：IPF/PECT납미립경균균,무명현취합현상；용함불동농도(0、200、400、800、1200、1600、2000μg/mL)IPF/PECT적배양기배양아간성섬유세포(HGFs)48 h후,각조간평균OD치량량상비차이균무통계학의의(P﹥0.05)；재0.1μg/mL LPS자격하동시가입60μg/mL적IPF혹IPF/PECT,병여HGFs공동배양10、24、48、72 h후,각시간점적전렬선소E2( PGE2)농도균위IPF/PECT조명현저우IPF조(P<0.05)；IPF/PECT체외석방IPF가지속32 d이상,약물루적석방량체85%。결론：본실험소제비적신형쌍친성재약온민응효IPF/PECT구유량호적생물안전성화완만석약공능,기항염효과명현우우IPF수용액。
AIM:To investigate the biosafety, anti-inflammatory effect and drug-release property of a no-vel PECT-based drug delivery system of ibuprofen( IPF) loaded amphiphilic thermosensitive hydrogel. METHODS:IPF/PECT nanoparticles ( IPF/PECT NPs) were manufactured by nanoprecipitation, then the particles were freeze-dried and dissolved into double distilled water to become a liquid solution. The morphology of the particles was ob-served by TEM, the anti-inflammatory effect of IPF/PECT nanoparticles was examined by MTT and ELISA with a hu-man gingival fibroblasts( HGFs) based inflammation model. RESULTS:The particles were uniform-sized and no ag-gregation was observed. After loading different concentrations (0, 200, 400, 800, 1,200, 1,600 and 2,000 μg/mL respectively) of IPF/PECT, the means of OD value of HGFs were 0. 29 ± 0. 01, 0. 28 ± 0. 01, 0. 29 ± 0. 02, 0. 29 ± 0.03,0.29±0.03,0.29±0.03,and0.28±0.02respectively(betweeneach2groups,P﹥0.05). Atevery point-in-time, the IPF/PECT group showed lower PGE2 level than IPF group(P<0. 05). The total release process could last for 32 days, with a cumulative release amount of 85%. CONCLUSION:The novel PECT-based drug de-livery system is biocompatable with slow-releasing property and anti-inflammatory effect.